Part 11 Audit Trails, Legacy Systems Subject To FDA Enforcement Discretion
This article was originally published in The Gray Sheet
Device manufacturers must continue to validate electronic recordkeeping and signature systems under ongoing FDA part 11 enforcement discretion, according to CDRH International Staff Director Christine Nelson
You may also be interested in...
Device manufacturers should prepare for variability in how inspectors interpret Part 11 requirements as FDA gears-up to communicate more specific guidelines to its field staff in the next several weeks
FDA will scale back enforcement of its electronic records and signatures rule (Part 11) for all FDA-regulated products while it reassesses the regulation in light of the agency's current good manufacturing practice initiative for drugs and biologics
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.